Colorectal Cancer
Experts
Contact us to join our network, learn more about our educational offerings, or inquire about joining our faculty. We are your source for up-to-date clinical information.
Want This Data Sent Straight To You?
Subscribe today and get credible, unbiased information from disease experts sent straight to your phone or inbox.
Mark Socinski, MD breaks down the ADAURA trial
Mark Socinski, MD breaks down the ADAURA trial and the data that may change how oncologists treat EGFR+ adjuvant NSCLC after complete tumor resection. The primary endpoint was Disease Free Survival (DFS) in Stage II/IIIA patients and the secondary endpoint was DFS in the overall population.
“The disease free survival endpoint is very impressive and hard to ignore. I think the central question is will that translate into an overall survival benefit.
Lung Cancer
Want This Data Sent Straight To You?
Subscribe today and get credible, unbiased information from disease experts sent straight to your phone or inbox.
CANT FIND WHAT YOU ARE LOOKING FOR?
GET IN TOUCH
Dr. Mark A. Socinski is a board-certified, fellowship trained medical oncologist, specializing in all thoracic malignancies, including small cell and non-small cell lung cancers and mesothelioma. He is an internationally recognized expert in the development of novel chemotherapy agents and treatment strategies for advanced non-small cell lung cancer and small cell lung cancer.
His research has focused on incorporating personalized medicine and molecular biomarkers in the treatment of lung cancer.
Dr. Socinski formerly served as Co-Chair of the Thoracic Malignancies Steering Committee for the National Cancer Institute. He also serves on the Respiratory Core Committee of the Cancer and Leukemia Group B (Alliance) and has been instrumental in the development of many cooperative clinical trials. He is the Executive Medical Director of the AdventHealth Cancer Institute.